Spinogenix Appoints Harvard Medical School Professor of Neurology Steven E. Arnold, MD, to Scientific Advisory Board

Appointment of Renowned Alzheimer's Expert to Support Spinogenix's Advancement of Neurodegenerative Disease Strategy and Translational Biomarker Development LOS ANGELES, July 9, 2026 /PRNewswire/ -- Spinogenix, Inc., a clinical-stage biopharmaceutical company pioneering novel therapeutics...

Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.